Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo.

Fiche publication

Date publication

décembre 2018

Journal

EJNMMI research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COLLIN Bertrand , Dr DECREAU Richard , Dr BELLAYE Pierre-Simon

Tous les auteurs :
Desvaux E, Courteau A, Bellaye PS, Guillemin M, Drouet C, Walker P, Collin B, Decréau RA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30574662

Résumé

Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with F-fluoromisonidazole (FMISO) for drug development purposes.

Mots clés

18F-Fluoromisonidazole (FMISO), BOLD, Cherenkov luminescence imaging (CLI), Colon cancer, Hypoxia, Magnetic resonance imaging, Positron emission tomography (PET)